Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) (NCT07684144)
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).
Who can join: Review the eligibility criteria below.
Location: Gilbert Center for Family Medicine — Gilbert, Arizona
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- Gilbert Center for Family Medicine — Gilbert, Arizona
- San Fernando Valley Health Institute — Canoga Park, California
- Core Healthcare Group — Cerritos, California
- Velocity Clinical Research Chula Vista — Chula Vista, California
- Empire Clinical Research — Pomona, California
- Optimus U Corporation — Miami, Florida
- San Marcus Research Clinic Inc — Miami Lakes, Florida
- Indago Research and Health Center — Miami Lakes, Florida
- Florida Institute for Clinical Research — Orlando, Florida
- Encore Medical Research of Weston LLC — Weston, Florida
- Conquest Research - Winter Park — Winter Park, Florida
- Iowa Diabetes Research — West Des Moines, Iowa
- Alliance for Multispecialty Research Newton — Newton, Kansas
- Alliance for Multispecialty Research LLC — Wichita, Kansas
- Alliance for Multispecialty Research - Kansas City — Kansas City, Missouri
- Palm Research Center Inc — Las Vegas, Nevada
- Premier Research — Trenton, New Jersey
- West Clinical Research — Morehead City, North Carolina
- Velocity Clinical Research - Cincinnati — Cincinnati, Ohio
- Velocity Clinical Research - Springdale — Cincinnati, Ohio
- Velocity Clinical Research - Providence — East Greenwich, Rhode Island
- Elligo Clinical Research Center — Austin, Texas
- Johnson County Clinical Trials Juno Bellaire — Bellaire, Texas
- Osvaldo A Brusco MD PA — Corpus Christi, Texas
- Soma Clinical Trials, LLC — Denison, Texas
📞 Contact the Study Coordinator
Phone: (866) 572-6436
Email: medinfo@amgen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Obesity
- Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools — Tampa, Florida
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity — Tucson, Arizona
- Piloting a Patient Navigator Program for Weight Loss — Philadelphia, Pennsylvania
- Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) — Mesa, Arizona
- Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects — Orlando, Florida
- Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans — Pittsburgh, Pennsylvania
Explore by condition: All Obesity clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.